Peptides are poised to go mainstream with this week’s launches from telehealth companies Hims & Hers and Noom, both of which announced they will be offering prescriptions for eligible patients.
Synthetic peptides are a broad category of short-chain amino acids. Initially popular among bodybuilders, certain drugs in the class have gained traction among a broad swath of people looking to optimize their health — whether to build muscle, feel more energetic, increase libido, or recover from injuries. But many compounded peptides that are marketed to consumers are experimental. They have not been approved by the Food and Drug Administration, nor are there randomized controlled trials showing their safety and efficacy in humans. The Department of Health and Human Services, however, has foregrounded the drugs under health secretary Robert F. Kennedy Jr., an avowed peptide enthusiast.
While peptide prescriptions were already offered by smaller telehealth companies, Hims (with a market cap of more than $3.5 billion) and Noom (a private company valued at $3.7 billion) are two of the industry’s dominant players, making the announcements a pivotal moment for peptides in the United States.
Continue to STAT+ to read the full story…
